ARTICLE | Finance

Taking heart

FDA approval launches diagnostics play BG Medicine on IPO road show

December 6, 2010 8:00 AM UTC

Bolstered by the recent FDA approval of its Galectin-3 test to assess the prognosis of chronic heart failure patients, molecular diagnostics play BG Medicine Inc. started an IPO road show and updated its S-1 last week.

The IPO is slated for the week of Dec. 13. The company hopes to sell 4.8 million shares at $13-$15. At $14, BG would raise $66.5 million and be valued at $248 million...